DexCom (NASDAQ:DXCM) PT Lowered to $87.00 at Leerink Partners

DexCom (NASDAQ:DXCM) had its target price trimmed by Leerink Partners from $90.00 to $87.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical device company’s stock.

Several other brokerages have also recently commented on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, October 12th. BTIG Research cut their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Canaccord Genuity Group reissued a “buy” rating and set a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. Robert W. Baird boosted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Finally, UBS Group cut their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $73.44 on Friday. The firm has a market cap of $29.21 billion, a PE ratio of 47.38, a PEG ratio of 2.26 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a fifty day moving average price of $70.11 and a 200 day moving average price of $97.95.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.34 EPS. Research analysts predict that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,824 shares of company stock valued at $126,390. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently bought and sold shares of DXCM. Wealth Enhancement Advisory Services LLC raised its stake in DexCom by 11.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 25,322 shares of the medical device company’s stock worth $3,512,000 after buying an additional 2,591 shares during the last quarter. Hodges Capital Management Inc. bought a new position in DexCom during the first quarter worth $347,000. Toth Financial Advisory Corp raised its stake in DexCom by 870.9% during the first quarter. Toth Financial Advisory Corp now owns 6,583 shares of the medical device company’s stock worth $913,000 after buying an additional 5,905 shares during the last quarter. Trilogy Capital Inc. bought a new position in DexCom during the first quarter worth $470,000. Finally, Congress Wealth Management LLC DE raised its stake in DexCom by 0.6% during the first quarter. Congress Wealth Management LLC DE now owns 168,657 shares of the medical device company’s stock worth $23,393,000 after buying an additional 952 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.